Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive biomarkers for decreased glomerular filtration rate in patients with type 2 diabetes mellitus
DOI:
https://doi.org/10.21527/2176-7114.2025.50.12283Keywords:
Diabetic Nephropathy, Glomerular Filtration, Biomarkers, Hematological ParametersAbstract
Diabetes mellitus is considered one of the major public health problems of the 21st century and is one of the most important risk factors for chronic kidney disease. The neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are biomarkers associated with systemic inflammation, measured through complete blood count, and have been investigated as biomarkers for other inflammatory diseases, showing promising results. In this context, diabetic nephropathy is associated with chronic low-grade inflammation. Therefore, the present study aimed to evaluate the correlation between leukocyte parameters and renal function biomarkers in patients with type 2 diabetes mellitus (T2DM). A total of 33 male patients with T2DM, with a mean age of 65 years, underwent clinical and laboratory assessment to evaluate hematological and biochemical parameters. Descriptive statistical analysis was performed using the Kolmogorov-Smirnov test for normality, Pearson’s test (for parametric data), or Spearman’s test (for nonparametric data), with statistical significance set at P ≤ 0.05. NLR and PLR were inversely correlated with decreased glomerular filtration rate and positively correlated with increased urea and creatinine concentrations. The use of NLR and PLR proved to be predictive biomarkers for reduced glomerular filtration rate in patients with T2DM, representing a low-cost tool in patient care.
References
1Amorim RG. et al. Doença renal do diabetes: cross-linking entre hiperglicemia, desequilíbrio redox e inflamação. Arquivos Brasileiros de Cardiologia. 2019; 112(5):577–587.
2Dwyer JP. et al. Renal dysfunction in the presence of normoalbuminuria in Type 2 Diabetes: Results from the DEMAND Study. Cardiorenal Medicine. 2011;2(1):1–10.
3N, Eunsung Mouradian MM. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA - Journal of the American Medical Association. 2011; 305(24):2532–2539.
4Wu L. et al. Annexin A1 alleviates kidney injury by promoting the resolution of inflammation in diabetic nephropathy. Kidney International. 2021;100(1):107-121.
5Faria JBL de. Atualização em fisiologia e fisiopatologia : Patogênese da nefropatia diabética. J Bras Nefrol. 2001;23(2):121-9
6Oliveira JEP de, Júnior RMM, Vencio S. Diretrizes da Sociedade Brasileira de Diabetes 2017-2018. São Paulo: [s.n.].
7Batista LKC. et al. Manuseio da doença renal crônica em pacientes com hipertensão e diabetes. J. bras. Nefrol. 2005;XXVII(1):8–13.
8CHAO CT. et al. The risk trajectory of different cardiovascular morbidities associated with chronic kidney disease among patients with newly diagnosed diabetes mellitus: a propensity score-matched cohort analysis. Cardiovascular Diabetology. 2021;20(1):86
9Yang Y, Li N, CHEN M. Survival outcomes and adverse events in patients with chronic kidney disease after coronary artery bypass grafting and percutaneous coronary intervention: a meta-analysis of propensity score-matching studies. Renal Failure. 2021; 43(1):606–616.
10Xi C. et al. A Nomogram Model that Predicts the Risk of Diabetic Nephropathy in Type 2 Diabetes Mellitus Patients: A Retrospective Study. Int J Endocrinol. 2021:6672444 DOI: 10.1155/2021/6672444
11Parlar H, Şaşkin H. Are pre and postoperative platelet to lymphocyte ratio and neutrophil to lymphocyte ratio associated with early postoperative aki following CABG? Brazilian Journal of Cardiovascular Surgery. 2018; 33(3):233–241.
12Ene-Iordache B. et al. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): A cross-sectional study. The Lancet Global Health. 2016;4(5):e307–e319.
13Eckstein SS, WEIGERT C, LEHMANN R. Divergent Roles of IRS (Insulin Receptor Substrate) 1 and 2 in Liver and Skeletal Muscle. Current Medicinal Chemistry. 2017;24(17): 1827-1852. DOI: 10.2174/0929867324666170426142826
14Kiya M. et al. Adipose Insulin Resistance and Decreased Adiponectin Are Correlated With Metabolic Abnormalities in Nonobese Men. The Journal of Clinical Endocrinology & Metabolism. 2021;106(5):e2228-e2238. DOI: 10.1210/clinem/dgab037.
15Hahn WS. et al. Proinflammatory cytokines differentially regulate adipocyte mitochondrial metabolism, oxidative stress, and dynamics. American Journal of Physiology - Endocrinology and Metabolism. 2014;306(9):e1033.
16Tabák AG. et al. Changes in C-reactive protein levels before type 2 diabetes and cardiovascular death: The Whitehall II study. European Journal of Endocrinology. 2010; 163(1):89-95.
17Dugani SB. et al. Association of Lipid, Inflammatory, and Metabolic Biomarkers with Age at Onset for Incident Coronary Heart Disease in Women. JAMA Cardiology. 2021;6(4):437-447. DOI: 10.1001/jamacardio.2020.7073.
18Huang W. et al. Neutrophil-lymphocyte ratio is a reliable predictive marker for early-stage diabetic nephropathy. Clinical Endocrinology. 2015;82(2):229-233.
19Couser WG. Patogênese e tratamento da glomerulonefrite - uma atualização. Jornal brasileiro de nefrologia. 2016; 38(1):107-122.
20Lou M. et al. Relationship between neutrophil-lymphocyte ratio and insulin resistance in newly diagnosed type 2 diabetes mellitus patients. BMC Endocrine Disorders. 2015;15(1). DOI: 10.1186/s12902-015-0002-9
21Chittawar S. et al. Neutrophil-lymphocyte ratio is a novel reliable predictor of nephropathy, retinopathy, and coronary artery disease in Indians with type-2 diabetes. Indian Journal of Endocrinology and Metabolism. 2017;21(6):864-870.
22Kahraman C. et al. The relationship between neutrophil-to-lymphocyte ratio and albuminuria in type 2 diabetic patients: A pilot study. Archives of Medical Science. 2016;12(3):571–575.
23Yodying H. et al. Prognostic Significance of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Oncologic Outcomes of Esophageal Cancer: A Systematic Review and Meta-analysis. Annals of Surgical Oncology. 2016;23(2):646–654.
24Afsar B. et al. An update on coronary artery disease and chronic kidney disease. International Journal of Nephrology. 2014;767424.
25Shiny A. et al. Association of neutrophil-lymphocyte ratio with glucose intolerance: An indicator of systemic inflammation in patients with type 2 diabetes. Diabetes Technology and Therapeutics. 2014;16(8):524-530.
26Akdoğan M, Yasemin UB, Huysal K. The association of hematologic inflammatory markers with atherogenic index in type 2 diabetic retinopathy patients. Clinical Ophthalmology. 2016;10:1797-1801.
27Efe E. et al. Platelet-to-lymphocyte ratio but not neutrophil-to-lymphocyte ratio predicts high on-treatment platelet reactivity in clopidogrel-treated patients with acute coronary syndrome. Indian Journal of Pharmacology. 2016;48(4):355-359.
28Chen H. et al. Presurgical platelet–lymphocyte ratio for prognosis in advanced hypopharyngeal squamous cell carcinoma in individuals undergoing radical resection. Acta Oto-Laryngologica. 2021;141(5):537-543.
29Llorente-Chávez A. et al. Thrombosis and thrombocytopenia in antiphospholipid syndrome: their association with mean platelet volume and hematological ratios. Thrombosis Research. 2021; 203:12–17.
30Marques P. et al. Serum inflammation-based scores in endocrine tumors. The Journal of Clinical Endocrinology & Metabolism. 2021;106(10):e3796-e3819.
31Soma P. et al. Flow cytometric analysis of platelets type 2 diabetes mellitus reveals “angry” platelets. Cardiovascular Diabetology. 2016; Article number:52(2016).
32Zubiaga L, Ruiz-Tovar J. Correlation of preoperative neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio with metabolic parameters in patients undergoing sleeve gastrectomy. Surgery for Obesity and Related Diseases. 2020;16(8):999–1004.
33Azab B. et al. Value of platelet/lymphocyte ratio as a predictor of all-cause mortality after non-ST-elevation myocardial infarction. Journal of Thrombosis and Thrombolysis. 2012; 34(3):326-334.
34Yu Y. et al. Pre-radiotherapy lymphocyte count and platelet-to-lymphocyte ratio may improve survival prediction beyond clinical factors in limited stage small cell lung cancer: model development and validation. Translational Lung Cancer Research. 2020;9(6):2315-2327.
35Sunbul M. et al. Neutrophil to lymphocyte and platelet to lymphocyte ratio in patients with dipper versus non-dipper hypertension. Clinical and Experimental Hypertension. 2014;36(4): 217-221.
36Sambel M. et al. Relationship between erectile dysfunction and the neutrophil to lymphocyte and platelet to lymphocyte ratios. International Journal of Impotence Research. 2018;30(1):27-35.
37Kawaguchi T. et al. C-reactive protein and mortality in hemodialysis patients: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephron - Clinical Practice. 2011; 117(2): c167-78. DOI: 10.1159/000320116
38Pérez-Morales RE. et al. Inflammation in diabetic kidney disease. Nephron. 2019;143(1):12-16.
39Mendes BB. Oliveira ACR, Alcântara KC de. Comparação das razões neutrófilo-linfócito e plaqueta-linfócito de indivíduos normoglicêmicos e hiperglicêmicos. Einstein. 2018;17(1):eAO4403
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Carla Luara Lima Padilha, Maicon Machado Sulzbacher, Pauline Brendler Goettems Fiorin, Mirna Stela Ludwig, Matias Nunes Frizzo
This work is licensed under a Creative Commons Attribution 4.0 International License.
By publishing in Revista Contexto & Saúde, authors agree to the following terms:
The works are licensed under the Creative Commons Atribuição 4.0 Internacional (CC BY 4.0) license, which allows:
Share — to copy and redistribute the material in any medium or format;
Adapt — to remix, transform, and build upon the material for any purpose, including commercial.
These permissions are irrevocable, provided that the following terms are respected:
Attribution — authors must be properly credited, with a link to the license and indication of any changes made.
No additional restrictions — no legal or technological measures may be applied that restrict the use permitted by the license.
Notes:
The license does not apply to elements in the public domain or covered by legal exceptions.
The license does not grant all rights necessary for specific uses (e.g., image rights, privacy, or moral rights).
The journal is not responsible for opinions expressed in the articles, which are the sole responsibility of the authors. The Editor, with the support of the Editorial Board, reserves the right to suggest or request modifications when necessary.
Only original scientific articles presenting research results of interest that have not been published or simultaneously submitted to another journal with the same objective will be accepted.
Mentions of trademarks or specific products are intended solely for identification purposes, without any promotional association by the authors or the journal.
License Agreement (for articles published from September 2025): Authors retain copyright over their article and grant Revista Contexto & Saúde the right of first publication.
